REDWOOD CITY, Calif., April 10, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndromes (MDS) as well as novel stem cell transplant conditioning regimes, today announced the appointment of David Hinds, as the Company’s Senior Vice President, Development Operations. “We are pleased to welcome David to our team. His outstanding track record in setting strategic directions for clinical research and operations will allow us to effectively advance our development programs for briquilimab,” said Ronald Martell, President and Chief Executive Officer of Jasper. “As we navigate through a critical phase in our advancement of this promising asset, David’s leadership will be instrumental in rapidly progressing briquilimab in chronic spontaneous urticaria and initiating chronic lower-risk MDS study, all while maintaining momentum in the SCID, Fanconi Anemia, and sickle cell disease transplant studies recruitment.” Mr. Hinds brings more than 25 years of experience in operations and clinical program development across multiple therapeutic areas, all phases of development, and all regions of the world. Throughout his career, Mr. Hinds held a number of leadership roles, most recently as Vice President and General Partner at ICON plc, the world’s leading clinical research organization. Previously he served as Vice President, Clinical Operations at PellePharm and Tioma Therapeutics. He also led the clinical development and operations strategy at Alios Biopharma, Takeda, Clinipace, Exelixis, Kai Pharmaceuticals, Genentech, Genitope Corporation, and Intermune. He directly contributed to the success of global products including Rituxan, Adcetris, Velcade, Truvada, Orbactiv, Pirfenidone, and Celebrex. Mr. Hinds earned a Masters of Business Administration from Moore School of Business, University of South Carolina, and a Bachelor of Science in Biology at The Citadel – The Military College of South Carolina. “I am thrilled to join the Jasper team at such an exciting time as the Company expands the development of briquilimab into chronic mast cell diseases and advances its novel conditioning approach for stem cell transplant”, said Mr. Hinds. “I look forward to contributing to the Jasper team by leveraging all the hard work that has been accomplished to date and executing on near-term clinical milestones.” About Jasper Jasper is a clinical-stage biotechnology company developing briquilimab, a monoclonal antibody targeting c-Kit (CD117) as a therapeutic for chronic mast and stem cell diseases such as chronic urticaria and lower to intermediate risk myelodysplastic syndromes (MDS) and as a conditioning agent for stem cell transplants for rare diseases such as sickle cell disease (SCD), Fanconi anemia (FA) and severe combined immunodeficiency (SCID). To date, briquilimab has a demonstrated efficacy and safety profile in over 130 dosed subjects and healthy volunteers, with clinical outcomes as a conditioning agent in SCID, acute myeloid leukemia (AML), MDS, FA, and SCD. In addition, briquilimab is being advanced as a transformational non-genotoxic conditioning agent for gene therapy. For more information, please visit us at www.jaspertherapeutics.com. Forward-Looking Statements Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding briquilimab’s potential, including with respect to its potential to address diseases such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndromes as well as novel stem cell transplant conditioning regimes, its potential to address a variety of patient populations by targeting c-Kit expressed on stem cells and mast cells and its efficacy and safety profile, pathways to market, the expansion of briquilimab development, Jasper’s expectations regarding the timing of clinical trials and recruitment for clinical trials and Jasper’s expectations regarding its cash and cash equivalents and planned operating and capital expenditures. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of Jasper and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Many actual events and circumstances are beyond the control of Jasper. These forward-looking statements are subject to a number of risks and uncertainties, including general economic, political and business conditions; the risk that the potential product candidates that Jasper develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; the risk that clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release; the risk that Jasper will be unable to successfully market or gain market acceptance of its product candidates; the risk that prior study results may not be replicated; the risk that Jasper’s product candidates may not be beneficial to patients or successfully commercialized; patients’ willingness to try new therapies and the willingness of physicians to prescribe these therapies; the effects of competition on Jasper’s business; the risk that third parties on which Jasper depends for laboratory, clinical development, manufacturing and other critical services will fail to perform satisfactorily; the risk that Jasper’s business, operations, clinical development plans and timelines, and supply chain could be adversely affected by the effects of health epidemics, including the ongoing COVID-19 pandemic; the risk that Jasper will be unable to obtain and maintain sufficient intellectual property protection for its investigational products or will infringe the intellectual property protection of others; and other risks and uncertainties indicated from time to time in Jasper’s filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2022. If any of these risks materialize or Jasper’s assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While Jasper may elect to update these forward-looking statements at some point in the future, Jasper specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Jasper’s assessments of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements. Contacts: John Mullaly (investors)LifeSci Advisors617-429-3548jmullaly@lifesciadvisors.com Jeet Mahal (investors)Jasper Therapeutics650-549-1403jmahal@jaspertherapeutics.com Lauren Barbiero (media)Real Chemistry646-564-2156lbarbiero@realchemistry.com
